These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9410069)

  • 1. [Pharmacoeconomics of meropenem versus imipenem/cilastatin].
    Marquina MC; Giráldez J; Idoate A
    Enferm Infecc Microbiol Clin; 1997 Sep; 15 Suppl 1():45-50. PubMed ID: 9410069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness study of imipenem/cilastatin versus meropenem in intra-abdominal infections.
    Attanasio E; Russo P; Carunchio G; Basoli A; Caprino L
    Dig Surg; 2000; 17(2):164-72. PubMed ID: 10781982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost efficacy of tazobactam/piperacillin versus imipenem/cilastatin in the treatment of intra-abdominal infection.
    Dietrich ES; Schubert B; Ebner W; Daschner F
    Pharmacoeconomics; 2001 Jan; 19(1):79-94. PubMed ID: 11252548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-utility analysis comparing meropenem with imipenem plus cilastatin in the treatment of severe infections in intensive care.
    Edwards SJ; Campbell HE; Plumb JM
    Eur J Health Econ; 2006 Mar; 7(1):72-8. PubMed ID: 16429296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Empiric carbapenem monotherapy in pediatric bone marrow transplant recipients.
    Nelson WK; Rayback PA; Quinones R; Giller RH
    Ann Pharmacother; 2002 Sep; 36(9):1360-5. PubMed ID: 12196052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients.
    Fournier A; Eggimann P; Pagani JL; Revelly JP; Decosterd LA; Marchetti O; Pannatier A; Voirol P; Que YA
    Burns; 2015 Aug; 41(5):956-68. PubMed ID: 25678084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evidence-based medicine, health costs and treatment of intra-abdominal infection].
    Badía X; Brosa M; Tellado JM
    Enferm Infecc Microbiol Clin; 1999; 17 Suppl 2():86-94. PubMed ID: 10605193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-minimization analysis of piperacillin/tazobactam versus imipenem/cilastatin for the treatment of serious infections: a Canadian hospital perspective.
    Marra FO; Frighetto LO; Marra CA; Sleigh KM; Stiver HG; Bryce EA; Reynolds RP; Jewesson PJ
    Ann Pharmacother; 1999 Feb; 33(2):156-62. PubMed ID: 10084409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective evaluation of piperacillin-tazobactam, imipenem-cilastatin and meropenem used on surgical floors at a tertiary care hospital in Saudi Arabia.
    Youssif E; Aseeri M; Khoshhal S
    J Infect Public Health; 2018; 11(4):486-490. PubMed ID: 29153444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meropenem versus imipenem/cilastatin in the treatment of hospitalized patients with skin and soft tissue infections.
    Nichols RL; Smith JW; Geckler RW; Wilson SE
    South Med J; 1995 Apr; 88(4):397-404. PubMed ID: 7716590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of an alternative meropenem dosing strategy compared with imipenem-cilastatin or traditional meropenem dosing after cefepime failure or intolerance in adults with neutropenic fever.
    Arnold HM; McKinnon PS; Augustin KM; Hladnik LM; Casabar E; Reichley RM; Dubberke ER; Westervelt P; Ritchie DJ
    Pharmacotherapy; 2009 Aug; 29(8):914-23. PubMed ID: 19637944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cefozopran, meropenem, or imipenem-cilastatin compared with cefepime as empirical therapy in febrile neutropenic adult patients: A multicenter prospective randomized trial.
    Nakane T; Tamura K; Hino M; Tamaki T; Yoshida I; Fukushima T; Tatsumi Y; Nakagawa Y; Hatanaka K; Takahashi T; Akiyama N; Tanimoto M; Ohyashiki K; Urabe A; Masaoka T; Kanamaru A;
    J Infect Chemother; 2015 Jan; 21(1):16-22. PubMed ID: 25239059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formulary review of the carbapenems: comparison of imipenem/cilastatin and meropenem.
    Richerson MA; Ambrose PG; Quintiliani R; Nightingale CH
    Conn Med; 1998 Mar; 62(3):165-9. PubMed ID: 9573653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients.
    McKinnon PS; Paladino JA; Grayson ML; Gibbons GW; Karchmer AW
    Clin Infect Dis; 1997 Jan; 24(1):57-63. PubMed ID: 8994756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meropenem versus imipenem-cilastatin for the treatment of hospitalized patients with complicated skin and skin structure infections: results of a multicenter, randomized, double-blind comparative study.
    Fabian TC; File TM; Embil JM; Krige JE; Klein S; Rose A; Melnick D; Soto NE
    Surg Infect (Larchmt); 2005; 6(3):269-82. PubMed ID: 16201937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter randomized trial comparing meropenem (1.5 g daily) and imipenem/cilastatin (2 g daily) in the hospital treatment of community-acquired pneumonia.
    Bartoloni A; Strohmeyer M; Corti G; Buonomini MI; Franchino L; Romanelli G; Moretti AM; De Vizzi GB; Petraglia A; Mancini P; Atzeni R; Fogliani V; Giura R; Paradisi F
    Drugs Exp Clin Res; 1999; 25(6):243-52. PubMed ID: 10713862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation.
    Lee LS; Kinzig-Schippers M; Nafziger AN; Ma L; Sörgel F; Jones RN; Drusano GL; Bertino JS
    Diagn Microbiol Infect Dis; 2010 Nov; 68(3):251-8. PubMed ID: 20851549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carbapenems in serious infections: a risk-benefit assessment.
    Norrby SR
    Drug Saf; 2000 Mar; 22(3):191-4. PubMed ID: 10738843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carbapenems in the treatment of severe community-acquired pneumonia in hospitalized elderly patients: a comparative study against standard therapy.
    Romanelli G; Cravarezza P; Pozzi A; Franchino L; Ravizzola G; Zulli R; Donati P; Prometti P; Grassi V
    J Chemother; 2002 Dec; 14(6):609-17. PubMed ID: 12583553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between in vitro and in vivo models of proconvulsive activity with the carbapenem antibiotics, biapenem, imipenem/cilastatin and meropenem.
    Day IP; Goudie J; Nishiki K; Williams PD
    Toxicol Lett; 1995 Apr; 76(3):239-43. PubMed ID: 7762010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.